Endologix to Collaborate With Japan Lifeline on Thoracic Endovascular Systems in Japan
September 11, 2017—Endologix, Inc. announced that it has signed a joint research and development agreement, as well as an exclusive distribution agreement, with Japan Lifeline Co., Ltd. (JLL) pertaining to the development and distribution of novel endovascular stent graft systems for the treatment of thoracic aortic diseases.
Under the terms of these agreements, the companies will jointly invest in the development, clinical research, and commercialization of the new thoracic systems. JLL has exclusive distribution rights to the devices in Japan, and Endologix intends to commercialize and sell the systems through its existing global sales force and distribution partners in countries other than Japan.
JLL is the exclusive distributor in Japan for Endologix products, including the AFX and AFX2 endograft systems for the treatment of abdominal aortic aneurysms. JLL will also facilitate the Japanese market launches of Endologix's Ovation and Nellix devices in the future.